Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure

International Journal of Cardiology

Volumn 93, Issue 1, 2004, Pages 45-48

  Bettencourt, Paulo ^a   Friões, Fernando ^a   Azevedo, Ana ^a   Dias, Paula ^a   Pimenta, Joana ^a   Rocha Gonçalves, Francisco ^a   Ferreira, António ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Brain natriuretic peptide; Heart failure; Mortality; Prognosis; Therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MORTALITY; MULTIVARIATE ANALYSIS; PHYSICIAN; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE;

EID: 0346056801     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(03)00115-3     Document Type: Article

References (17)

1. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 316:1987;1429-1435.
2. Effects of enalapril on survival of patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 325:1991;293-302.
3. Cleland J.G., Swedberg K., Poole-Wilson P.A. Successes and failures of current treatment of heart failure. Lancet. 352:1998;S119-128.
4. Cowburn P.J., Cleland J.G., Coats A.J., Coats A.J., Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 19:1998;696-710.
5. van den Broek S.A., van Veldhuisen D.J., de Graeff P.A., Landsman M.L., Hillege H., Liek I. Comparison between New York Association classification and peak oxygen consumption in the assessment of functional status and prognosis in patients with mild to moderate chronic congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 70:1992;359-363.
6. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure. Prognostic role of plasma brain peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 96:1997;509-516.
7. Tsutamoto T., Wada A., Maeda K., et al. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Eur Heart J. 20:1999;1799-1807.
8. Bettencourt P., Ferreira A., Dias P., et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail. 6:2000;306-313.
9. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 355:2000;1126-1130.
10. Murdoch D.R., McDonagh T.A., Byrne J., et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomised comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 138:1999;1126-1132.
11. Kohno M., Minami M., Kano H., et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensive with left ventricular hypertrophy. Metabolism. 49:2000;1356-1360.
12. Brunner-La Rocca H.P., Weilenmann D., Kiowski W., Maly F.E., Candinas R., Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J. 138:1999;654-662.
13. Ohta Y., Watanabe K., Nakazawa M., et al. Carvedilol enhances atrial and brain natriuretic peptide mRNA expression and release in rat heart. J Cardiovasc Pharmacol. 36:2000;S19-23.
14. Luchner A., Burnett J.C. Jr., Jougasaki M., et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 32:1998;1839-1844.
15. Kawai K., Hata K., Takaoka H., Kawai H., Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J. 141:2000;925-932.
16. Fujimura M., Yasumura Y., Ishida Y., et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail. 6:2000;3-10.
17. Stanek B., Frey B., Hulsmann M., et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced ventricular dysfunction. J Am Coll Cardiol. 38:2001;436-442.